1
|
Meade R, Chao Y, Harroun N, Li C, Hafezi S, Hsu FF, Semenkovich CF, Zayed MA. Ceramides in peripheral arterial plaque lead to endothelial cell dysfunction. JVS Vasc Sci 2023; 4:100181. [PMID: 38077163 PMCID: PMC10704331 DOI: 10.1016/j.jvssci.2023.100181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Accepted: 10/22/2023] [Indexed: 02/12/2024] Open
Abstract
Background Peripheral arterial atheroprogression is increasingly prevalent, and is a risk factor for major limb amputations in individuals with risk factors such as diabetes. We previously demonstrated that bioactive lipids are significantly altered in arterial tissue of individuals with diabetes and advanced peripheral arterial disease. Methods Here we evaluated whether sphingolipid ceramide 18:1/16:0 (C16) is a cellular regulator in endothelial cells and peripheral tibial arterial tissue in individuals with diabetes. Results We observed that C16 is the single most elevated ceramide in peripheral arterial tissue from below the knee in individuals with diabetes (11% increase, P < .05). C16 content in tibial arterial tissue positively correlates with sphingomyelin (SPM) content in patients with and without diabetes (r2 = 0.5, P < .005; r2 = 0.17, P < .05; respectively). Tibial arteries of individuals with diabetes demonstrated no difference in CERS6 expression (encoding ceramide synthase 6; the predominate ceramide synthesis enzyme), but higher SMPD expression (encoding sphingomyelin phosphodiesterase that catalyzes ceramide synthesis from sphingomyelins; P < .05). SMPD4, but not SMPD2, was particularly elevated in maximally diseased (Max) tibial arterial segments (P < .05). In vitro, exogenous C16 caused endothelial cells (HUVECs) to have decreased proliferation (P < .03), increased apoptosis (P < .003), and decreased autophagy (P < .008). Selective knockdown of SMPD2 and SMPD4 decreased native production of C16 (P < .01 and P < .001, respectively), but only knockdown of SMPD4 rescued cellular proliferation (P < .005) following exogenous supplementation with C16. Conclusions Our findings suggest that C16 is a tissue biomarker for peripheral arterial disease severity in the setting of diabetes, and can impact endothelial cell viability and function. Clinical relevance Peripheral arterial disease and its end-stage manifestation known as chronic limb-threatening ischemia (CLTI) represent ongoing prevalent and intricate medical challenges. Individuals with diabetes have a heightened risk of developing CLTI and experiencing its complications, including wounds, ulcers, and major amputations. In the present study, we conducted a comprehensive examination of the molecular lipid composition within arterial segments from individuals with CLTI, and with and without diabetes. Our investigations unveiled a striking revelation: the sphingolipid ceramide 18:1/16:0 emerged as the predominant ceramide species that was significantly elevated in the peripheral arterial intima below the knee in patients with diabetes. Moreover, this heightened ceramide presence is associated with a marked impairment of endothelial cell function and viability. Additionally, our study revealed a concurrent elevation in the expression of sphingomyelin phosphodiesterases, enzymes responsible for catalyzing ceramide synthesis from sphingomyelins, within maximally diseased arterial segments. These findings underscore the pivotal role of ceramides and their biosynthesis enzymes in the context of CLTI, offering new insights into potential therapeutic avenues for managing this challenging disease process.
Collapse
Affiliation(s)
- Rodrigo Meade
- Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO
| | - Yang Chao
- Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO
| | - Nikolai Harroun
- Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO
| | - Chenglong Li
- Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO
| | - Shahab Hafezi
- Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO
| | - Fong-Fu Hsu
- Division of Endocrinology, Lipid, and Metabolism, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO
| | - Clay F. Semenkovich
- Division of Endocrinology, Lipid, and Metabolism, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO
| | - Mohamed A. Zayed
- Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO
- Department of Surgery, Veterans Affairs St. Louis Health Care System, St. Louis, MO
- Department of Radiology, Washington University School of Medicine, St. Louis, MO
- Division of Molecular Cell Biology, Washington University School of Medicine, St. Louis, MO
- Department of Biomedical Engineering, Washington University, McKelvey School of Engineering, St. Louis, MO
| |
Collapse
|
2
|
Ménégaut L, Laubriet A, Crespy V, Leleu D, Pilot T, Van Dongen K, de Barros JPP, Gautier T, Petit JM, Thomas C, Nguyen M, Steinmetz E, Masson D. Inflammation and oxidative stress markers in type 2 diabetes patients with Advanced Carotid atherosclerosis. Cardiovasc Diabetol 2023; 22:248. [PMID: 37710315 PMCID: PMC10503074 DOI: 10.1186/s12933-023-01979-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Accepted: 09/03/2023] [Indexed: 09/16/2023] Open
Abstract
BACKGROUND Type 2 diabetes mellitus (T2DM) is a major global health issue and a significant risk factor for atherosclerosis. Atherosclerosis in T2DM patients has been associated with inflammation, insulin resistance, hyperglycemia, dyslipidemia, and oxidative stress. Identifying molecular features of atherosclerotic plaques in T2DM patients could provide valuable insights into the pathogenesis of the disease. METHODS The MASCADI (Arachidonic Acid Metabolism in Carotid Stenosis Plaque in Diabetic Patients) study aimed to investigate the increase of 2-arachidonoyl-lysophatidylcholine (2-AA-LPC) in carotid plaques from T2DM and control patients and to explore its association with plaque vulnerability as well as with blood and intra-plaque biomarkers altered during diabetes. RESULTS In a population of elderly, polymedicated patients with advanced stage of atherosclerosis, we found that T2DM patients had higher systemic inflammation markers, such as high-sensitivity C-reactive protein (hsCRP) and IL-1β, higher levels of oxysterols, increased triglyceride levels, and decreased HDL levels as compared to control patients. Furthermore, 2-AA-LPC was significantly enriched in plaques from diabetic patients, suggesting its potential role in diabetic atherosclerosis. Interestingly, 2-AA-LPC was not associated with systemic markers related to diabetes, such as hsCRP, triglycerides, or HDL cholesterol. However, it was significantly correlated with the levels of inflammatory markers within the plaques such as lysophospholipids and 25-hydroxycholesterol, strengthening the link between local inflammation, arachidonic acid metabolism and diabetes. CONCLUSION Our study is in line with a key role for inflammation in the pathogenesis of diabetic atherosclerosis and highlights the involvement of 2-AA-LPC. Further research is needed to better understand the local processes involved in the alteration of plaque composition in T2DM and to identify potential therapeutic targets. TRIAL REGISTRATION The MASCADI was registered on ClinicalTrials.gov (clinical registration number: NCT03202823).
Collapse
Affiliation(s)
- Louise Ménégaut
- Université Bourgogne, LNC UMR1231, Dijon, France
- INSERM, UMR1231, Dijon, France
- Université Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
- CHU Dijon, Laboratory of Clinical Chemistry, Dijon, France
| | - Aline Laubriet
- Department of Cardiovascular and Thoracic Surgery, CHU Dijon, Dijon, France
| | - Valentin Crespy
- Department of Cardiovascular and Thoracic Surgery, CHU Dijon, Dijon, France
| | - Damien Leleu
- Université Bourgogne, LNC UMR1231, Dijon, France
- INSERM, UMR1231, Dijon, France
- Université Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
- CHU Dijon, Laboratory of Clinical Chemistry, Dijon, France
| | - Thomas Pilot
- Université Bourgogne, LNC UMR1231, Dijon, France
- INSERM, UMR1231, Dijon, France
- Université Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - Kevin Van Dongen
- Université Bourgogne, LNC UMR1231, Dijon, France
- INSERM, UMR1231, Dijon, France
- Université Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - Jean-Paul Pais de Barros
- Université Bourgogne, LNC UMR1231, Dijon, France
- INSERM, UMR1231, Dijon, France
- Université Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
- Lipidomic Analytic Platform, Université Bourgogne Franche-Comté, Dijon, France
| | - Thomas Gautier
- Université Bourgogne, LNC UMR1231, Dijon, France
- INSERM, UMR1231, Dijon, France
- Université Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - Jean-Michel Petit
- Université Bourgogne, LNC UMR1231, Dijon, France
- INSERM, UMR1231, Dijon, France
- Université Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
- Department of Endocrinology and metabolic diseases, CHU Dijon, Dijon, France
| | - Charles Thomas
- Université Bourgogne, LNC UMR1231, Dijon, France
- INSERM, UMR1231, Dijon, France
- Université Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - Maxime Nguyen
- Université Bourgogne, LNC UMR1231, Dijon, France
- INSERM, UMR1231, Dijon, France
- Université Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
- CHU Dijon Department of Anesthesiology and Intensive Care, Dijon, France
| | - Eric Steinmetz
- Department of Cardiovascular and Thoracic Surgery, CHU Dijon, Dijon, France
| | - David Masson
- Université Bourgogne, LNC UMR1231, Dijon, France.
- INSERM, UMR1231, Dijon, France.
- Université Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France.
- CHU Dijon, Laboratory of Clinical Chemistry, Dijon, France.
- UFR des sciences de santé, Bvd Jeanne d'Arc, Dijon, 21000, France.
| |
Collapse
|
3
|
Wang C, Zhao H, Xu K, Du Y, Liu J, Wang J, Jiang Y. Fecal metabolomics reveals the positive effect of ethanol extract of propolis on T2DM mice. FOOD SCIENCE AND HUMAN WELLNESS 2023. [DOI: 10.1016/j.fshw.2022.07.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
4
|
Ménégaut L, Laubriet A, Crespy V, Nguyen M, Petit JM, Tarris G, Pilot T, Varin A, Choubley H, Bergas V, de Barros JPP, Thomas C, Steinmetz E, Masson D. Profiling of lipid mediators in atherosclerotic carotid plaques from type 2 diabetic and non-diabetic patients. Prostaglandins Leukot Essent Fatty Acids 2022; 184:102477. [PMID: 35952424 DOI: 10.1016/j.plefa.2022.102477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Revised: 07/18/2022] [Accepted: 08/03/2022] [Indexed: 12/29/2022]
Abstract
BACKGROUND AND AIMS Diabetes is associated with an accelerated development of atherosclerosis. Specific mechanisms related to diabetes and hyperglycemia may play a role in this process. In particular, alterations of arachidonic acid (AA) metabolism have been reported. Our main goal was to investigate for differences in the concentration of LTB4 and RvD1 as well as selected cyclooxygenase-derived mediators in carotid plaques from diabetic and non-diabetic patients. We also aimed to analyze the relationship between omega 6 and omega 3 Poly-Unsaturated Fatty acids (PUFAs) content in the plaques and the concentrations of these lipid mediators. METHODS 29 type 2 diabetic patients and 30 control patients admitted for surgical treatment of carotid stenosis were enrolled in the present study. Carotid plaques were harvested for in-depth lipidomic profiling. RESULTS No differences for LTB4 or other lipid mediators were observed between diabetic and non-diabetic patients. RvD1 levels were below the threshold of quantification in most of the samples. A significant correlation was found between LTB4 and 5(S)-HETE levels. Omega 3 enrichment was not significantly different between control and diabetic plaques. There was a negative correlation between DHA/AA ratio and the level of 5(S)-HETE while there was a positive association with TXB2 and PGD2 concentrations. CONCLUSION-PERSPECTIVES Our results does not support the hypothesis of a specific involvement of LTB4 or COX-derived mediators in diabetic atherosclerosis. The relationship between DHA enrichment and the concentrations of specific inflammatory mediators within the plaque is of interest and will need to be confirmed in larger studies.
Collapse
Affiliation(s)
- Louise Ménégaut
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France; CHU Dijon, Laboratory of Clinical Chemistry, Dijon, France
| | - Aline Laubriet
- CHU Dijon, Department of Cardiovascular Surgery, Dijon, France
| | - Valentin Crespy
- CHU Dijon, Department of Cardiovascular Surgery, Dijon, France
| | - Maxime Nguyen
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France; CHU Dijon Department of Anesthesiology and Intensive Care, Dijon, France
| | - Jean-Michel Petit
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France; CHU Dijon, Department of Endocrinology and metabolic diseases, Dijon, France
| | | | - Thomas Pilot
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - Alexis Varin
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France; Lipidomic Analytic Platform, Université Bourgogne Franche-Comté, Dijon, France
| | - Hélène Choubley
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France; Lipidomic Analytic Platform, Université Bourgogne Franche-Comté, Dijon, France
| | - Victoria Bergas
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France; Lipidomic Analytic Platform, Université Bourgogne Franche-Comté, Dijon, France
| | - Jean-Paul Pais de Barros
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France; Lipidomic Analytic Platform, Université Bourgogne Franche-Comté, Dijon, France
| | - Charles Thomas
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - Eric Steinmetz
- CHU Dijon, Department of Cardiovascular Surgery, Dijon, France
| | - David Masson
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France; CHU Dijon, Laboratory of Clinical Chemistry, Dijon, France.
| |
Collapse
|
5
|
Engel C, Meade R, Harroun N, Penrose A, Shafqat M, Jin X, DeSilva G, Semenkovich C, Zayed M. Altered Peroxisome Proliferator-Activated Receptor Alpha Signaling in Variably Diseased Peripheral Arterial Segments. Front Cardiovasc Med 2022; 9:834199. [PMID: 35783870 PMCID: PMC9248745 DOI: 10.3389/fcvm.2022.834199] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Accepted: 05/04/2022] [Indexed: 11/25/2022] Open
Abstract
Objective Peripheral atherosclerosis that accumulates in the extracranial carotid and lower extremity arteries can lead to significant morbidity and mortality. However, atherosclerotic disease progression is often not homogenous and is accelerated by diabetes. We previously observed increased phospholipid content in minimally (Min)-diseased arterial segments compared to maximally (Max)-diseased segments. Since Peroxisome Proliferator-Activated Receptor alpha (PPARα) is a key regulator of lipid metabolism, we hypothesized that it may have differential expression and signaling in Min vs. Max-diseased peripheral arterial segments. Methods Eighteen patients who underwent carotid endarterectomy (CEA), and 34 patients who underwent major lower extremity amputation were prospectively enrolled into a vascular tissue biobank. Min and Max-diseased segments were obtained in real-time from CEA plaque and amputated lower extremity arterial segments. mRNA and protein were isolated from specimens and the relative expression of ppara, and its downstream genes Acyl-CoA Oxidase 1 (acox1) and Carnitine Palmitoyltransferase 1A (cpt1a) were also evaluated. We evaluated gene expression and protein content relative to atherosclerotic disease severity and clinical diabetes status. Gene expression was also evaluated relative to Hemoglobin A1c and serum lipid profiles. Results In CEA segments of patients with diabetes, we observed significantly higher ppara and acox1 gene expression (p < 0.01 and p < 0.001 respectively), and higher PPARα protein content (p < 0.05). Hemoglobin A1c significantly correlated with expression of ppara (R2 = 0.66, p < 0.001), acox1 (R2 = 0.31, p < 0.05), and cpt1a (R2 = 0.4, p < 0.05). There was no significant difference in gene expression between Min vs. Max-diseased CEA plaque segments. Conversely, in lower extremity arterial segments of patients with diabetes, we observed significantly lower ppara, acox1, and cpt1a expression (p < 0.05, p < 0.001, and p < 0.0001 respectively). Interestingly, CPT1A content was lower in arterial segments of patients with diabetes (p < 0.05). Hemoglobin A1c and HDL-cholesterol had negative correlations with ppara (R2 = 0.44, p < 0.05; R2 = 0.42, p < 0.05; respectively). Conclusion This study demonstrates the significant differential expression of ppara and its immediate downstream genes in human carotid and lower extremity arteries relative to disease severity and diabetes. These findings highlight that mechanisms that influence atheroprogression in the carotid and lower extremities peripheral arteries are not homogenous and can be impacted by patient diabetes status and serum cholesterol profiles. Further elucidating these differential molecular mechanisms can help improve targeted therapy of atherosclerosis in different peripheral arterial beds.
Collapse
Affiliation(s)
- Connor Engel
- Section of Vascular Surgery, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO, United States
| | - Rodrigo Meade
- Section of Vascular Surgery, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO, United States
| | - Nikolai Harroun
- Section of Vascular Surgery, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO, United States
| | - Amanda Penrose
- Section of Vascular Surgery, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO, United States
| | - Mehreen Shafqat
- Section of Vascular Surgery, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO, United States
| | - Xiaohua Jin
- Section of Vascular Surgery, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO, United States
| | - Gayan DeSilva
- Section of Vascular Surgery, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO, United States
| | - Clay Semenkovich
- Division of Endocrinology, Metabolism and Lipid Research, Department of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO, United States
| | - Mohamed Zayed
- Section of Vascular Surgery, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO, United States,Division of Molecular Cell Biology, Washington University in St. Louis School of Medicine, St. Louis, MO, United States,Department of Biomedical Engineering, McKelvey School of Engineering, Washington University in St. Louis, St. Louis, MO, United States,Veterans Affairs St. Louis Health Care System, St. Louis, MO, United States,*Correspondence: Mohamed Zayed,
| |
Collapse
|
6
|
Zayed MA, Jin X, Yang C, Belaygorod L, Engel C, Desai K, Harroun N, Saffaf O, Patterson BW, Hsu FF, Semenkovich CF. CEPT1-Mediated Phospholipogenesis Regulates Endothelial Cell Function and Ischemia-Induced Angiogenesis Through PPARα. Diabetes 2021; 70:549-561. [PMID: 33214136 PMCID: PMC7881870 DOI: 10.2337/db20-0635] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Accepted: 11/12/2020] [Indexed: 11/13/2022]
Abstract
De novo phospholipogenesis, mediated by choline-ethanolamine phosphotransferase 1 (CEPT1), is essential for phospholipid activation of transcription factors such as peroxisome proliferator-activated receptor α (PPARα) in the liver. Fenofibrate, a PPARα agonist and lipid-lowering agent, decreases amputation incidence in patients with diabetes. Because we previously observed that CEPT1 is elevated in carotid plaque of patients with diabetes, we evaluated the role of CEPT1 in peripheral arteries and PPARα phosphorylation (Ser12). CEPT1 was found to be elevated in diseased lower-extremity arterial intima of individuals with peripheral arterial disease and diabetes. To evaluate the role of Cept1 in the endothelium, we engineered a conditional endothelial cell (EC)-specific deletion of Cept1 via induced VE-cadherin-CreERT2-mediated recombination (Cept1Lp/LpCre +). Cept1Lp/LpCre + ECs demonstrated decreased proliferation, migration, and tubule formation, and Cept1Lp/LpCre + mice had reduced perfusion and angiogenesis in ischemic hind limbs. Peripheral ischemic recovery and PPARα signaling were further compromised by streptozotocin-induced diabetes and ameliorated by feeding fenofibrate. Cept1 endoribonuclease-prepared siRNA decreased PPARα phosphorylation in ECs, which was rescued with fenofibrate but not PC16:0/18:1. Unlike Cept1Lp/LpCre + mice, Cept1Lp/LpCre + Ppara -/- mice did not demonstrate hind-paw perfusion recovery after feeding fenofibrate. Therefore, we demonstrate that CEPT1 is essential for EC function and tissue recovery after ischemia and that fenofibrate rescues CEPT1-mediated activation of PPARα.
Collapse
Affiliation(s)
- Mohamed A Zayed
- Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO
- Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO
- Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO
- VA St. Louis Health Care System, St. Louis, MO
| | - Xiaohua Jin
- Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO
| | - Chao Yang
- Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO
| | - Larisa Belaygorod
- Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO
| | - Connor Engel
- Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO
| | - Kshitij Desai
- Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO
| | - Nikolai Harroun
- Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO
| | - Omar Saffaf
- Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO
| | - Bruce W Patterson
- Center for Human Nutrition, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO
| | - Fong-Fu Hsu
- Division of Endocrinology, Metabolism and Lipid Research, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO
| | - Clay F Semenkovich
- Division of Endocrinology, Metabolism and Lipid Research, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO
| |
Collapse
|
7
|
Hasanpour M, Iranshahy M, Iranshahi M. The application of metabolomics in investigating anti-diabetic activity of medicinal plants. Biomed Pharmacother 2020; 128:110263. [DOI: 10.1016/j.biopha.2020.110263] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2020] [Revised: 05/08/2020] [Accepted: 05/10/2020] [Indexed: 12/21/2022] Open
|
8
|
Ménégaut L, Jalil A, Thomas C, Masson D. Macrophage fatty acid metabolism and atherosclerosis: The rise of PUFAs. Atherosclerosis 2019; 291:52-61. [PMID: 31693943 DOI: 10.1016/j.atherosclerosis.2019.10.002] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2019] [Revised: 09/26/2019] [Accepted: 10/09/2019] [Indexed: 01/24/2023]
Abstract
Among the pathways involved in the regulation of macrophage functions, the metabolism of unsaturated fatty acids is central. Indeed, unsaturated fatty acids act as precursors of bioactive molecules such as prostaglandins, leukotrienes, resolvins and related compounds. As components of phospholipids, they have a pivotal role in cell biology by regulating membrane fluidity and membrane-associated cellular processes. Finally, polyunsaturated fatty acids (PUFAs) are also endowed with ligand properties for numerous membrane or nuclear receptors. Although myeloid cells are dependent on the metabolic context for the uptake of essential FAs, recent studies showed that these cells autonomously handle the synthesis of n-3 and n-6 long chain PUFAs such as arachidonic acid and eicosapentaenoic acid. Moreover, targeting PUFA metabolism in macrophages influences pathological processes, including atherosclerosis, by modulating macrophage functions. Omics evidence also supports a role for macrophage PUFA metabolism in the development of cardiometabolic diseases in humans. Currently, there is a renewed interest in the role of n-3/n-6 PUFAs and their oxygenated derivatives in the onset of atherosclerosis and plaque rupture. Purified n-3 FA supplementation appears as a potential strategy in the treatment and prevention of cardiovascular diseases. In this context, the ability of immune cells to handle and to synthesize very long chain PUFA must absolutely be integrated and better understood.
Collapse
Affiliation(s)
- Louise Ménégaut
- Univ. Bourgogne Franche-Comté, LNC UMR1231, F-21000, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, F-21000, Dijon, France
| | - Antoine Jalil
- Univ. Bourgogne Franche-Comté, LNC UMR1231, F-21000, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, F-21000, Dijon, France
| | - Charles Thomas
- Univ. Bourgogne Franche-Comté, LNC UMR1231, F-21000, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, F-21000, Dijon, France
| | - David Masson
- Univ. Bourgogne Franche-Comté, LNC UMR1231, F-21000, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, F-21000, Dijon, France.
| |
Collapse
|
9
|
De Silva GS, Desai K, Darwech M, Naim U, Jin X, Adak S, Harroun N, Sanchez LA, Semenkovich CF, Zayed MA. Circulating serum fatty acid synthase is elevated in patients with diabetes and carotid artery stenosis and is LDL-associated. Atherosclerosis 2019; 287:38-45. [PMID: 31202106 DOI: 10.1016/j.atherosclerosis.2019.05.016] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/15/2019] [Revised: 05/04/2019] [Accepted: 05/23/2019] [Indexed: 01/11/2023]
Abstract
BACKGROUND AND AIMS Diabetes is an independent risk factor for carotid artery stenosis (CAS). Fatty acid synthase (FAS), an essential de novo lipogenesis enzyme, has increased activity in the setting of diabetes that leads to altered lipid metabolism. Circulating FAS (cFAS) was recently observed in the blood of patients with hyperinsulinemia and cancer. We thought to evaluate the origin of cFAS and its role in diabetes-associated CAS. METHODS Patients with diabetes and no diabetes, undergoing carotid endarterectomy (CEA) for CAS, were prospectively enrolled for collection of plaque and fasting serum. FPLC was used to purify lipoprotein fractions, and ELISA was used to quantify cFAS content and activity. Immunoprecipitation (IP) was used to evaluate the affinity of cFAS to LDL-ApoB. RESULTS Patients with CAS had higher cFAS activity (p < 0.01), and patients with diabetes had higher cFAS activity than patients with no diabetes (p < 0.05). cFAS activity correlated with serum glucose (p = 0.03, r2 = 0.35), and cFAS content trended with plaque FAS content (p = 0.06, r2 = 0.69). cFAS was predominantly in LDL cholesterol fractions of patients with CAS (p < 0.001), and IP of cFAS demonstrated pulldown of ApoB. Similar to patients with diabetes, db/db mice had highest levels of serum cFAS (p < 0.01), and fasL-/- (tissue-specific liver knockdown of FAS) mice had the lowest levels of cFAS (p < 0.001). CONCLUSIONS Serum cFAS is higher in patients with diabetes and CAS, appears to originate from the liver, and is LDL cholesterol associated. We postulate that LDL may be serving as a carrier for cFAS that contributes to atheroprogression in carotid arteries of patients with diabetes.
Collapse
Affiliation(s)
- Gayan S De Silva
- (a)Washington University School of Medicine, Department of Surgery, Section of Vascular Surgery, St. Louis, MO, USA
| | - Kshitij Desai
- (a)Washington University School of Medicine, Department of Surgery, Section of Vascular Surgery, St. Louis, MO, USA
| | - Malik Darwech
- (a)Washington University School of Medicine, Department of Surgery, Section of Vascular Surgery, St. Louis, MO, USA
| | - Uzma Naim
- (a)Washington University School of Medicine, Department of Surgery, Section of Vascular Surgery, St. Louis, MO, USA
| | - Xiaohua Jin
- (a)Washington University School of Medicine, Department of Surgery, Section of Vascular Surgery, St. Louis, MO, USA
| | - Sangeeta Adak
- Washington University School of Medicine, Department of Internal Medicine, Division of Endocrinology, Lipid, and Metabolism, St. Louis, MO, USA
| | - Nikolai Harroun
- (a)Washington University School of Medicine, Department of Surgery, Section of Vascular Surgery, St. Louis, MO, USA
| | - Luis A Sanchez
- (a)Washington University School of Medicine, Department of Surgery, Section of Vascular Surgery, St. Louis, MO, USA
| | - Clay F Semenkovich
- Washington University School of Medicine, Department of Internal Medicine, Division of Endocrinology, Lipid, and Metabolism, St. Louis, MO, USA
| | - Mohamed A Zayed
- (a)Washington University School of Medicine, Department of Surgery, Section of Vascular Surgery, St. Louis, MO, USA; Veterans Affairs St. Louis Health Care System, St. Louis, MO, USA.
| |
Collapse
|
10
|
Chen J, Zheng L, Hu Z, Wang F, Huang S, Li Z, Zheng P, Zhang S, Yi T, Li H. Metabolomics Reveals Effect of Zishen Jiangtang Pill, a Chinese Herbal Product on High-Fat Diet-Induced Type 2 Diabetes Mellitus in Mice. Front Pharmacol 2019; 10:256. [PMID: 30941040 PMCID: PMC6434817 DOI: 10.3389/fphar.2019.00256] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2018] [Accepted: 02/28/2019] [Indexed: 12/22/2022] Open
Abstract
A Chinese herbal decoction, Zishen Jiangtang Pill (ZJP), has been clinically prescribed to diabetic patients to prevent excessive blood sugar levels for decades. However, the potential mechanisms of this action have not been well investigated. The purpose of this study was to explore the metabolic variations in response to ZJP treatment for an animal model of obese type 2 diabetes. An UHPLC-Orbitrap/MS-based metabolomics tool was conducted to reveal the potential mechanisms of ZJP on diabetic mice. The treatment with ZJP significantly restored the increased levels of insulin, glucose and total cholesterol in high-fat diet mice. A total of 26 potential biomarkers were found and identified in serum samples, amongst which 24 metabolites were robustly affected and driven back to the control-like levels after ZJP treatment. By analyzing the metabolic pathways, glutathione metabolism, steroid hormone biosynthesis and glycerophospholipid metabolism were suggested to be closely involved in diabetes disease. From the above outcomes, it can be concluded that ZJP exhibits a promising anti-diabetic activity, largely due to the regulation of phospholipid metabolism, including phosphatidylcholines, lysophosphatidylcholines, and phosphatidylinositol.
Collapse
Affiliation(s)
- Jianping Chen
- Shenzhen Key Laboratory of Hospital Chinese Medicine Preparation, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China
| | - Lin Zheng
- Shenzhen Key Laboratory of Hospital Chinese Medicine Preparation, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China
| | - Zhaoliu Hu
- Shenzhen Key Laboratory of Hospital Chinese Medicine Preparation, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China
| | - Fochang Wang
- The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China
| | - Shiying Huang
- The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China
| | - Zhonggui Li
- Shenzhen Key Laboratory of Hospital Chinese Medicine Preparation, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China
| | - Ping Zheng
- Shenzhen Key Laboratory of Hospital Chinese Medicine Preparation, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China
| | - Shangbin Zhang
- Shenzhen Key Laboratory of Hospital Chinese Medicine Preparation, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China
| | - Tiegang Yi
- Shenzhen Key Laboratory of Hospital Chinese Medicine Preparation, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China
| | - Huilin Li
- Shenzhen Key Laboratory of Hospital Chinese Medicine Preparation, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China
| |
Collapse
|